RecruitingPhase 1NCT07226843

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies

Sponsor

Eli Lilly and Company

Enrollment

460 participants

Start Date

Apr 17, 2026

Study Type

INTERVENTIONAL

Conditions

Follicular Lymphoma Lymphoma Diffuse Large B-cell Lymphoma, Non-Hodgkin's

Summary

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called LY4584180 and a drug called Rituximab for people with follicular lymphoma, lymphoma diffuse large b-cell, and other related conditions. The study is currently recruiting participants at 46 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLY4584180

administered orally

DRUGRituximab

administered through IV infusion

Locations(46)

Mayo Clinic - Scottsdale

Scottsdale, Arizona, United States

City of Hope

Duarte, California, United States

University of California, Los Angeles (UCLA) - Medical Center

Los Angeles, California, United States

University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

University of Miami - Sylvester Cancer Center

Miami, Florida, United States

Florida Cancer Specialists - Sarasota

Sarasota, Florida, United States

Emory University Hospital

Atlanta, Georgia, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Mayo Clinic - Rochester

Rochester, Minnesota, United States

Columbia University

New York, New York, United States

University of Rochester

Rochester, New York, United States

The Ohio State University (OSU)

Columbus, Ohio, United States

Oregon Health & Science University (OHSU)

Portland, Oregon, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Texas Oncology - DFW (Sammons CC)

Dallas, Texas, United States

Baylor College of Medicine

Houston, Texas, United States

University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)

Seattle, Washington, United States

Froedtert Hospital and the Medical College of Wisconsin

Milwaukee, Wisconsin, United States

CHU de Nantes - Hotel-Dieu

Nantes, France

Institut Curie

Paris, France

CHU Bordeaux - Hopital Haut-Leveque - Centre Francois Magendie

Pessac, France

HCL Centre Hospitalier Lyon Sud

Pierre-Bénite, France

Oncopole Claudius Regaud

Toulouse, France

Charite Universitaetsmedizin Berlin

Berlin, Germany

Universitaetsklinikum Koeln (AoeR)

Cologne, Germany

Universitaetsklinikum Essen

Essen, Germany

Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet

Frankfurt am Main, Germany

IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola

Bologna, Italy

Istituto Europeo di Oncologia

Milan, Italy

National Cancer Center Hospital East

Chiba, Japan

Okayama University Hospital

Okayama, Japan

Cancer Institute Hospital of JFCR

Tokyo, Japan

Pratia Onkologia Katowice

Katowice, Poland

Pratia MCM Krakow

Krakow, Poland

AIDPORT Sp. z o.o.

Skorzewo, Poland

Instytut Hematologii i Transfuzjologii w Warszawie

Warsaw, Poland

Institut Catala d'Oncologia - L'Hospitalet

Barcelona, Spain

South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

Madrid, Spain

King's College Hospital

London, United Kingdom

The Royal Marsden NHS Foundation Trust

London, United Kingdom

Nottingham City Hospital

Nottingham, United Kingdom

Derriford Hospital

Plymouth, United Kingdom

University Hospital Southampton NHS Foundation Trust

Southampton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07226843

Related Trials

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716127 locations

Clonal Evolution in Follicular Lymphoma

NCT031909281 location

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

NCT0763447110 locations

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686175 locations

Allo HSCT Using RIC and PTCy for Hematological Diseases

NCT058056051 location